Coppola Nicola, Zampino Rosa, Sagnelli Caterina, Bellini Giulia, Marrone Aldo, Stanzione Maria, Capoluongo Nicolina, Boemio Adriana, Minichini Carmine, Adinolfi Luigi Elio, Maione Sabatino, Del Giudice Emanuele Miraglia, Sagnelli Evangelista, Rossi Francesca
Department of Mental Health and Public Medicine, Second University of Naples, Naples, Italy.
Internal Medicine and Hepatology, Second University of Naples, Naples, Italy.
PLoS One. 2014 Jun 18;9(6):e99450. doi: 10.1371/journal.pone.0099450. eCollection 2014.
To evaluate in anti-HCV-positive patients the clinical impact of the rs35761398 variant of the CNR2 gene leading to the substitution of Gln (Q) of codon 63 of the cannabinoid receptor 2 (CB2) with Arg (R).
253 consecutive anti-HCV-/HCV-RNA-positive patients were enrolled, of whom 53 were HCV carriers with persistently normal ALT (PNALT group) and 200 had a history of steadily abnormal serum ALT values (abnormal ALT group). All patients were naive for antiviral therapy and were screened for the CNR2 rs35761398 polymorphism by a TaqMan assay.
Subjects in the PNALT group, compared with those in the abnormal ALT group were older (58.5±12 vs. 50.7±12.4 years, p = 0.001), more frequently female (66% vs. 42%, p = 0.003), with lower body mass index (BMI) (24.5±3.1 vs. 26.6±4.6, p = 0.003), and more frequently with HCV genotype 2 (43.1% vs 17.7%, p = 0.0002) and CB2-63 QQ variant (34% vs. 11%, p = 0.0001). Considering all 253 patients, no difference in the demographic, biochemical, or virological data was observed between patients in the different CB2-63 variants. The logistic regression analysis identified CB2-63 QQ, HCV genotype 2, older age and lower BMI as independent predictors of PNALT (p<0.00001).
The CB2-63 QQ variant in HCV patients was independently associated with the PNALT status.
评估大麻素受体2（CB2）第63位密码子的谷氨酰胺（Q）被精氨酸（R）取代的CNR2基因rs35761398变体在抗丙型肝炎病毒（HCV）阳性患者中的临床影响。
纳入253例连续的抗HCV/HCV-RNA阳性患者，其中53例为丙氨酸氨基转移酶（ALT）持续正常的HCV携带者（PNALT组），200例有血清ALT值持续异常病史（ALT异常组）。所有患者均未接受过抗病毒治疗，采用TaqMan分析检测CNR2 rs35761398多态性。
与ALT异常组相比，PNALT组患者年龄更大（58.5±12岁对50.7±12.4岁，p = 0.001），女性比例更高（66%对42%，p = 0.003），体重指数（BMI）更低（24.5±3.1对26.6±4.6，p = 0.003），HCV基因2型比例更高（43.1%对17.7%，p = 0.0002），CB2-63 QQ变体比例更高（34%对11%，p = 0.0001）。在所有253例患者中，不同CB2-63变体患者的人口统计学、生化或病毒学数据均无差异。逻辑回归分析确定CB2-63 QQ、HCV基因2型、年龄较大和BMI较低是PNALT的独立预测因素（p<0.00001）。
HCV患者中的CB2-63 QQ变体与PNALT状态独立相关。
